BioNTech SE Statistics
Total Valuation
BioNTech SE has a market cap or net worth of $20.64 billion. The enterprise value is $3.41 billion.
| Market Cap | 20.64B |
| Enterprise Value | 3.41B |
Important Dates
The next confirmed earnings date is Monday, May 6, 2024, before market open.
| Earnings Date | May 6, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
BioNTech SE has 237.73 million shares outstanding.
| Shares Outstanding | 237.73M |
| Owned by Insiders (%) | 62.84% |
| Owned by Institutions (%) | 18.33% |
| Float | 88.96M |
Valuation Ratios
The trailing PE ratio is 21.17 and the forward PE ratio is 7.04. BioNTech SE's PEG ratio is 0.04.
| PE Ratio | 21.17 |
| Forward PE | 7.04 |
| PS Ratio | 4.86 |
| Forward PS | 7.32 |
| PB Ratio | 0.96 |
| P/FCF Ratio | 4.15 |
| PEG Ratio | 0.04 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 2.30, with an EV/FCF ratio of 0.69.
| EV / Earnings | 3.30 |
| EV / Sales | 0.80 |
| EV / EBITDA | 2.30 |
| EV / EBIT | 2.64 |
| EV / FCF | 0.69 |
Financial Position
The company has a current ratio of 9.43, with a Debt / Equity ratio of 0.03.
| Current Ratio | 9.43 |
| Quick Ratio | 9.17 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.48 |
| Debt / FCF | 0.14 |
| Interest Coverage | 50.63 |
Financial Efficiency
Return on equity (ROE) is 4.60% and return on invested capital (ROIC) is 2.59%.
| Return on Equity (ROE) | 4.60% |
| Return on Assets (ROA) | 4.20% |
| Return on Capital (ROIC) | 2.59% |
| Revenue Per Employee | $691,885 |
| Profits Per Employee | $168,542 |
| Employee Count | 6,133 |
| Asset Turnover | 0.17 |
| Inventory Turnover | 1.50 |
Taxes
In the past 12 months, BioNTech SE has paid $272.75 million in taxes.
| Income Tax | 272.75M |
| Effective Tax Rate | 20.88% |
Stock Price Statistics
The stock price has decreased by -28.72% in the last 52 weeks. The beta is 0.23, so BioNTech SE's price volatility has been lower than the market average.
| Beta (1Y) | 0.23 |
| 52-Week Price Change | -28.72% |
| 50-Day Moving Average | 91.27 |
| 200-Day Moving Average | 101.40 |
| Relative Strength Index (RSI) | 39.28 |
| Average Volume (30 Days) | 626,491 |
Short Selling Information
| Short Interest | 3.08M |
| Short Previous Month | 3.08M |
| Short % of Shares Out | 6.42% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 4.33 |
Income Statement
In the last 12 months, BioNTech SE had revenue of $4.24 billion and earned $1.03 billion in profits. Earnings per share was $4.08.
| Revenue | 4.24B |
| Gross Profit | 3.43B |
| Operating Income | 736.14M |
| Pretax Income | 1.26B |
| Net Income | 1.03B |
| EBITDA | 1.49B |
| EBIT | 1.29B |
| Earnings Per Share (EPS) | $4.08 |
Balance Sheet
The company has $17.94 billion in cash and $717.69 million in debt, giving a net cash position of $17.23 billion or $72.47 per share.
| Cash & Cash Equivalents | 17.94B |
| Total Debt | 717.69M |
| Net Cash | 17.23B |
| Net Cash Per Share | $72.47 |
| Equity / Book Value | 21.59B |
| Book Value Per Share | 90.81 |
| Working Capital | 18.61B |
Cash Flow
In the last 12 months, operating cash flow was $5.73 billion and capital expenditures -$752.24 million, giving a free cash flow of $4.98 billion.
| Operating Cash Flow | 5.73B |
| Capital Expenditures | -752.24M |
| Free Cash Flow | 4.98B |
| FCF Per Share | $20.93 |
Margins
Gross margin is 80.89%, with operating and profit margins of 17.35% and 24.36%.
| Gross Margin | 80.89% |
| Operating Margin | 17.35% |
| Pretax Margin | 29.80% |
| Profit Margin | 24.36% |
| EBITDA Margin | 35.01% |
| EBIT Margin | 30.40% |
| FCF Margin | 117.24% |
Dividends & Yields
BioNTech SE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | n/a |
| Buyback Yield | 2.18% |
| Shareholder Yield | 2.18% |
| Earnings Yield | 5.01% |
| FCF Yield | 24.11% |
Analyst Forecast
The average price target for BioNTech SE is $127.58, which is 46.97% higher than the current price. The consensus rating is "Buy".
| Price Target | $127.58 |
| Price Target Difference | 46.97% |
| Analyst Consensus | Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (5Y) | 7.32% |
| EPS Growth Forecast (5Y) | 1.62% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BioNTech SE has an Altman Z-Score of 6.67 and a Piotroski F-Score of 7.
| Altman Z-Score | 6.67 |
| Piotroski F-Score | 7 |